Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CARsgen Therapeutics Holdings Limited
科濟藥業控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2171)

VOLUNTARY ANNOUNCEMENT ABSTRACTS OF CT1190B AND CT071 PUBLISHED AT ASH 2026 ANNUAL MEETING

This announcement is made by CARsgen Therapeutics Holdings Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**" or "**CARsgen**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the "**Board**") announces that the abstract of the research results of CT1190B (an allogeneic CAR T-cell product candidate targeting CD19/CD20) in the treatment of relapsed/refractory large B cell lymphoma and the abstract of the research results of CT071 (an autologous CAR T-cell product candidate targeting GPRC5D) in the treatment of relapsed/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM) have been published at the 68th Annual Meeting of the American Society of Hematology (ASH). The data of both product candidates will be presented as poster presentations at the Annual Meeting of ASH. Updated research results of CT0596 (an allogeneic CAR T-cell product candidate targeting BCMA) in the treatment of R/R MM and primary plasma cell leukemia will be published in a separate announcement of the Company in December 2026. Further details will be provided on the Company's website www.carsgen.com.

ABOUT CT1190B

CT1190B is a CD19/CD20-targeted allogeneic CAR T-cell therapy developed based on CARsgen's THANK-u Plus® platform. Registrational Phase I clinical trial for refractory/relapse large B-cell lymphoma is ongoing.

ABOUT CT071

CT071 is a CAR T-cell therapy candidate developed utilizing the proprietary CARcelerate® platform of CARsgen targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma or relapsed/refractory plasma cell leukemia. An investigator-initiated trial (NCT05838131) is ongoing in China to evaluate the preliminary safety and efficacy of CT071 for the treatment of relapsed/refractory multiple myeloma or plasma cell leukemia. Another investigator-initiated trial (NCT06407947) is ongoing in China for the treatment of HR-NDMM.

ABOUT CT0596

CT0596 is an allogeneic BCMA-targeted CAR T-cell therapy developed using CARsgen's proprietary THANK-u Plus® platform. It is currently being evaluated in registrational Phase I trial for R/R MM. Previous IITs have shown that CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals in R/R MM and primary plasma cell leukemia. Further investigation is planned in additional plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells.

ABOUT THE COMPANY

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"CAR"	chimeric antigen receptor
"CAR T"	chimeric antigen receptor T cell
"GPRC5D"	G protein-coupled receptor, class C, group 5, member D, a protein that is highly expressed on the surface of malignant plasma cells with limited expression on normal tissues

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, CT1190, CT071 and CT0596, successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

Cautionary Language Regarding Forward-Looking Statements

All statements in this announcement that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this announcement. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this announcement might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this announcement.

By order of the Board
CARsgen Therapeutics Holdings Limited
Dr. Zonghai LI
Chairman

Hong Kong, November 5, 2026

As at the date of this announcement, the Board comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Ronggang XIE as non-executive Director; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as independent non-executive Directors.

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.